While the vast majority of M&A deals announced so far this year are in the hundreds of million dollars, licensing agreements have been getting ever bigger.
Just last week, Takeda (TYO: 4502) punted a record upfront of $4 billion, plus $2 billion in milestone, on an accord with Nimbus; today US pharma giant Merck & Co (NYSE: MRK) is going even further.
Merck says it has entered into an exclusive license and collaboration agreement with Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical (SHE: 002422), to develop seven investigational pre-clinical antibody-drug conjugates (ADC) for the treatment of cancer. Sichuan Kelun shares dipped nearly 2% on the news
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze